All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Targeted Strategies Push the Envelope for BRAF V600E–, MET Exon 14–, and KRAS G12C–Mutated Metastatic NSCLC

November 17th 2025

Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.

Neladalkib Proves Effective in TKI-Pretreated, Advanced ALK+ NSCLC

November 17th 2025

Neladalkib elicited responses and was active in the CNS in TKI-pretreated patients with advanced ALK-positive NSCLC, including lorlatinib-naive patients.

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma

November 17th 2025

Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

Roswell Park Achieves National Accreditation for Rectal Cancer Care

November 17th 2025

Roswell Park Comprehensive Cancer Center is pleased to announce the recent accreditation of its rectal cancer program by the National Accreditation Program for Rectal Cancer.

PanTRKare Approved in China as Companion Diagnostic for Entrectinib in NTRK+ Solid Tumors

November 17th 2025

PanTRKare was approved in China as a companion diagnostic to identify patients with NTRK fusion–positive solid tumors who may be eligible for entrectinib.

FDA Grants Fast Track Designation to 4A10 for Relapsed/Refractory Acute Lymphoblastic Leukemia

November 17th 2025

The FDA has granted fast track designation to 4A10 for relapsed/refractory ALL.

New OncLive Podcast Series Launches With Focus on Gynecologic Oncology

November 17th 2025

OncLive has launched a new podcast series, From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD.

Five Under 5: Top Oncology Videos for the Week of 11/9

November 16th 2025

The top 5 OncLive TV videos of the week cover insights in breast cancer, uveal melanoma, prostate cancer, and multiple myeloma.

Advances With Checkpoint Inhibitors, T-Cell Engagers, and ADCs Converge to Reshape the SCLC Treatment Paradigm

November 16th 2025

Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.

Beyond the Genome: Exploring New Frontiers in NSCLC Management

November 15th 2025

Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.

Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC

November 15th 2025

Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.

Immunotherapy Advances in SCLC Highlight Promise, Limitations, and Biomarker Needs

November 15th 2025

Christine Hann, MD, PhD, discusses how recently presented SCLC data inform treatment decision-making across the LS-SCLC and ES-SCLC settings.

The OncFive: Top Oncology Articles for the Week of 11/9

November 15th 2025

The FDA has approved ziftomenib for NPM1-positive acute myeloid leukemia, has accepted a NDA for 177Lu-edotreotide for GEP-NETs, and more.

AMT-253 Demonstrates Early Efficacy and Manageable Safety in Melanoma

November 15th 2025

AMT-253 delivered durable responses in patients with melanoma with manageable toxicity, supporting continued development.

Phase 3 Data Illuminate Advancing Roles for T-DXd and Combination Approaches in HER2+ Breast Cancer

November 14th 2025

Yuan Yuan, MD, PhD, expands on several key studies informing the current and evolving use of ADCs and dual-pathway targeting in HER2-positive breast cancer.

Post-Operative Lymphatic ctDNA Data Shows Superior Sensitivity for Detecting Residual Disease in HPV-Independent HNSCC

November 14th 2025

Post-operative lymphatic ctDNA results exceeded plasma assays in detecting residual disease and predicting recurrence in HPV-independent HNSCC.

B7-H3–Targeted ADC HN-20093 Shows Strong Efficacy, Is Still Safe at Higher Dose in R/R Sarcomas

November 14th 2025

Lu Xie, MD, discusses phase 2 efficacy and safety data with the B7-H3–targeted ADC HS-20093 in relapsed/refractory sarcomas.

Adjuvant Satri-Cel Displays Preliminary Activity in Pancreatic Ductal Adenocarcinoma

November 14th 2025

Satri-cel displayed preliminary efficacy when used as adjuvant treatment in patients with pancreatic ductal adenocarcinoma.

Researchers Develop New AI Tool That Makes Detection of Skin Cancer More Accurate

November 14th 2025

A new method enhances the ability of artificial intelligence models to detect and diagnose skin cancer in individuals with darker skin.

FDA Grants Fast Track Designation to FOG-001 for Desmoid Tumors

November 14th 2025

The FDA granted fast track designation to FOG-001 for the treatment of patients with desmoid tumors.